PayPal seeks to challenge Amazon and Shopify with Fastlane checkout. Analyst predicts $100-250M revenue boost by FY26 and competitive edge over Apple Pay and Google Pay.
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.